Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + cyclophosphamide + doxorubicin
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves **capecitabine**, a nucleoside metabolic inhibitor that is converted to fluorouracil in the body, inhibiting DNA synthesis; **cyclophosphamide**, an alkylating agent that interferes with DNA replication; and **doxorubicin**, an anthracycline that intercalates DNA strands, preventing cell division. It is used in cancer treatment, particularly for breast cancer.
02
Targets
DNATOP2A (DNA topoisomerase II)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + cyclophosphamide + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + cyclophosphamide + doxorubicin.